Synthesis and pharmacological evaluation of SNC80 analogues with a bridged piperazine ring

ChemMedChem

Volumn 4, Issue 12, 2009, Pages 2111-2122

  Holl, Ralph ^a   Jung, Bettina ^a   Schepmann, Dirk ^a   Humpf, Hans Ulrich ^a   Grünert, Renate ^b   Bednarski, Patrick J ^b   Englberger, Werner ^c   Wünsch, Bernhard ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c GRÜNENTHAL GMBH   (Germany)

Author keywords

receptor agonists; Bridged piperazines; Cytotoxicity; Medicinal chemistry; Structure affinity relationships

Indexed keywords

4 [(8 ALLYL 4 BENZYLIDENE 6,8 DIAZABICYCLO[3.2.2]NON 6 YL]METHYL] N,N DIETHYLBENZAMIDE; 4 [(8 ALLYL 4 BENZYLOXY 6,8 DIAZABICYCLO[3.2.2]NON 6 YL)METHYL] N,N DIETHYLBENZAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; 4 [ALPHA (8 ALLYL 4 OXO 6,8 DIAZABICYCLO[3.2.2]NONAN 6 YL) ALPHA PHENYLMETHYL] N,N DIETHYLBENZAMIDE; 4 [ALPHA (8 ALLYL 6,8 DIAZABICYCLO[3.2.2]NON 6 YL)BENZYL] N,N DIETHYLBENZAMIDE; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; CISPLATIN; HALOPERIDOL; KAPPA OPIATE RECEPTOR; MELPHALAN; MU OPIATE RECEPTOR; PIPERAZINE DERIVATIVE; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR AFFINITY; STEREOCHEMISTRY;

BENZAMIDES; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LIGANDS; MOLECULAR STRUCTURE; PIPERAZINES; PROTEIN BINDING; RECEPTORS, OPIOID, DELTA;

EID: 73449148738     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200900358     Document Type: Article

References (22)

1. A. D. Corbett, G. Henderson, A. T. McKnight, S. J. Paterson, Br. J. Pharmacol. 2006, 147, 153- 162.
2. G. Dondio, S. Ronzoni, P. Petrillo, Exp. Opin. Therap. Pat. 1997, 7, 1075 -1098.
3. G. Dondio, S. Ronzoni, P. Petrillo, Exp. Opin. Therap. Pat. 1999, 9, 353 -374.
4. S. N. Calderon, R. B. Rothman, F. Porreca, J. L. Flippen-Anderson, R. W. McNutt, H. Xu, L. E. Smith, E. J. Bilsky, P. Davis, K. C. Rice, J. Med. Chem. 1994, 37, 2125 -2128.
5. B. Jung, W. Englberger, B. Wünsch, Arch. Pharm. 2005, 338, 281 -290.
6. B. Jung, W. Englberger, R. Fröhlich, D. Schepmann, K. Lehmkuhl, B. Wünsch, Bioorg. Med. Chem. 2008, 16, 2870- 2885.
7. R. Holl, D. Schepmann, R. Grünert, P. J. Bednarski, B. Wünsch, Bioorg. Med. Chem. 2009, 17, 777- 793.
8. R. Holl, D. Schepmann, R. Fröhlich, R. Grünert, P. J. Bednarski, B. Wünsch, J. Med. Chem. 2009, 52, 2126 -2137.
9. F. Karrer, DE Patent 2418295, 1974.
10. F. Karrer, DE Patent 2418343, 1974.
11. R. Maier, P. Müller, E. Woitun, R. Hurnaus, M. Mark, B. Eisele, R. Budzinski, G. Hallermayer, DE Patent 4407138, 1995.
12. S. N. Calderon, K. C. Rice, R. B. Rothman, F. Porreca, J. L. Flippen-Anderson, H. Kayakiri, H. Xu, K. Becketts, L. E. Smith, E. J. Bilsky, P. Davis, R. Horvath, J. Med. Chem. 1997, 40, 695 -704.
13. Y. Cheng, W. H. Prusoff, Biochem. Pharmacol. 1973, 22, 3099 - 3108.
14. R. Quirion, W. D. Bowen, Y. Itzhak, J. L. Junien, J. M. Musacchio, R. B. Rothman, T. P. Su, S. W. Tam, D. P. Taylor, Trends Pharmacol. Sci. 1992, 13, 85-86.
15. J. M. Walker, W. D. Bowen, F. O. Walker, R. R. Matsumoto, B. De Costa, K. C. Rice, Pharmacol. Rev. 1990, 42, 355- 402.
16. C. A. Maier, B. Wünsch, J. Med. Chem. 2002, 45, 438- 448.
17. C. Geiger, C. Zelenka, M. Weigl, R. Fröhlich, B. Wibbeling, K. Lehmkuhl, D. Schepmann, R. Gruenert, P. J. Bednarski, B. Wünsch, J. Med. Chem. 2007, 50, 6144 -6153.
18. U. Wirt, D. Schepmann, B. Wünsch, Eur. J. Org. Chem. 2007, 462 -475.
19. M. M. Bradford, Anal. Biochem. 1976, 72, 248 -254.
20. D. L. DeHaven-Hudkins, L. C. Fleissner, F. Y. Ford-Rice, Eur. J. Pharmacol. Mol. Pharmacol. Sect. 1992, 227, 371- 378.
21. R. H. Mach, C. R. Smith, S. R. Childers, Life Sci. 1995, 57, PL57 - 62.
22. K. Bracht, Boubakari, R. Grünert, P. J. Bednarski, Anticancer Drugs 2006, 17, 41- 51.